董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edwin M. Kania | 男 | Director | 68 | 未披露 | 未持股 | 2026-03-09 |
| Stephanie Lovell | 女 | Director | 66 | 未披露 | 未持股 | 2026-03-09 |
| Waleed Hassanein | 男 | Director,President and Chief Executive Officer | 57 | 52.40万美元 | 未持股 | 2026-03-09 |
| Edward M. Basile | 男 | Director | 78 | 未披露 | 未持股 | 2026-03-09 |
| Thomas J. Gunderson | 男 | Director | 75 | 未披露 | 未持股 | 2026-03-09 |
| David Weill | 男 | Director | 62 | 未披露 | 未持股 | 2026-03-09 |
| James R. Tobin | 男 | Chairman of Board | 81 | 未披露 | 未持股 | 2026-03-09 |
| Merilee Raines | 女 | Director | 70 | 未披露 | 未持股 | 2026-03-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Waleed Hassanein | 男 | Director,President and Chief Executive Officer | 57 | 52.40万美元 | 未持股 | 2026-03-09 |
| Tamer Khayal | 男 | Senior Vice President of International | 57 | 41.58万美元 | 未持股 | 2026-03-09 |
| Gerardo Hernandez | 男 | Chief Financial Officer and Treasurer | -- | 未披露 | 未持股 | 2026-03-09 |
| Nicholas Corcoran | 男 | Senior Vice President of Supply Chain and Operations | -- | 未披露 | 未持股 | 2026-03-09 |
| Matthew Forsyth | -- | Senior Vice President,General Counsel and Corporate Secretary | -- | 未披露 | 未持股 | 2026-03-09 |
| Giovanni Cecere | -- | Chief Commercial Officer | -- | 未披露 | 未持股 | 2026-03-09 |
董事简历
中英对照 | 中文 | 英文- Edwin M. Kania
-
Edwin M. Kania，他是Flagship Ventures公司（总部位于波士顿的风险资本公司）的联席创始人，并担任一些基金的管理合伙人。他曾担任Flagship Ventures公司的主席（2001年至2014年）。2000年共同创立Flagship Ventures公司之前，他曾担任OneLiberty Ventures公司及其前身公司（Morgan Holland Ventures）的普通合伙人。他的直接投资经验涉及了100多家公司。2004年以来，他曾一直任职Acceleron Pharma公司（临床阶段生物制药公司，专注于调节细胞的生长）的董事会。他也曾任职Aspect Medical公司、EXACT Sciences公司和其它公共和私人公司的董事会。他拥有达特茅斯学院（Dartmouth College）的物理学士学位，以及哈佛大学商学院（Harvard Business School）的工商管理硕士学位。
Edwin M. Kania was co-founder of Flagship Ventures and served as Flagship's Chairman between 2001 and 2014. Mr. Kania continues as Managing Partner for the three Flagship funds raised during that period. Mr. Kania also serves as Managing Partner for the predecessor OneLiberty Funds that were an early lead investor in the company. During Mr. Kania's 35 years in the venture capital industry, he has served on the boards of numerous privately and publicly held companies, including previous board positions at Acceleron Pharma and Selecta Biosciences. Mr. Kania earned his Bachelor's degree in physics from Dartmouth College and his MBA from Harvard Business School. - Edwin M. Kania，他是Flagship Ventures公司（总部位于波士顿的风险资本公司）的联席创始人，并担任一些基金的管理合伙人。他曾担任Flagship Ventures公司的主席（2001年至2014年）。2000年共同创立Flagship Ventures公司之前，他曾担任OneLiberty Ventures公司及其前身公司（Morgan Holland Ventures）的普通合伙人。他的直接投资经验涉及了100多家公司。2004年以来，他曾一直任职Acceleron Pharma公司（临床阶段生物制药公司，专注于调节细胞的生长）的董事会。他也曾任职Aspect Medical公司、EXACT Sciences公司和其它公共和私人公司的董事会。他拥有达特茅斯学院（Dartmouth College）的物理学士学位，以及哈佛大学商学院（Harvard Business School）的工商管理硕士学位。
- Edwin M. Kania was co-founder of Flagship Ventures and served as Flagship's Chairman between 2001 and 2014. Mr. Kania continues as Managing Partner for the three Flagship funds raised during that period. Mr. Kania also serves as Managing Partner for the predecessor OneLiberty Funds that were an early lead investor in the company. During Mr. Kania's 35 years in the venture capital industry, he has served on the boards of numerous privately and publicly held companies, including previous board positions at Acceleron Pharma and Selecta Biosciences. Mr. Kania earned his Bachelor's degree in physics from Dartmouth College and his MBA from Harvard Business School.
- Stephanie Lovell
-
分离完成后，Stephanie Lovell将担任我们的董事会成员。Lovell女士自2015年7月起担任马萨诸塞州蓝十字蓝盾（Blue Cross Blue Shield of Massachusetts，Inc.，简称BCBSMA）的执行Vice President、医疗保险和首席法律官。Lovell女士此前曾于2011年12月至2015年7月担任BCBSMA的高级副总裁and General Counsel。加入BCBSMA之前，Lovell从2007年3月到2011年12月担任Boston Medical Center行政and General Counsel高级副总裁。她此前也曾担任the Massachusetts Office of the Attorney的首席助理司法部长，以及the Massachusetts State Ethics Commission的执行董事。Lovell女士目前担任新英格兰法律基金会（New England Law Foundation）和合伙企业（Partnership，Inc.）的董事，并担任马萨诸塞州纳税人基金会（Massachusetts纳税人基金会）的受托人。她也是波士顿律师基金会（Boston Bar Foundation）的赠款委员会主席，也是Goodwill Industries of Massachusetts的投资委员会成员。Lovell在Hamilton College获得哲学学士学位，在Boston University School of Law获得法学博士学位。
Stephanie Lovell will serve as a member of our board of directors upon completion of this separation. Ms. Lovell has served as the executive vice president, Medicare and chief legal officer for Blue Cross Blue Shield of Massachusetts, Inc., or BCBSMA, since July 2015. Ms. Lovell previously served as the senior vice president and general counsel of BCBSMA from December 2011 to July 2015. Prior to BCBSMA, Ms. Lovell was the senior vice president of administration and general counsel for Boston Medical Center from March 2007 to December 2011. She also previously served as the first assistant attorney general in the Massachusetts Office of the Attorney General and as the executive director for the Massachusetts State Ethics Commission. Ms. Lovell currently serves as a director of the New England Law Foundation and The Partnership, Inc., and as a trustee of the Massachusetts Taxpayers Foundation. She also chairs the grants committee of the Boston Bar Foundation and is a member of the investment committee of Goodwill Industries of Massachusetts.Ms. Lovell received a B.A. in philosophy from Hamilton College and a J.D. from Boston University School of Law. - 分离完成后，Stephanie Lovell将担任我们的董事会成员。Lovell女士自2015年7月起担任马萨诸塞州蓝十字蓝盾（Blue Cross Blue Shield of Massachusetts，Inc.，简称BCBSMA）的执行Vice President、医疗保险和首席法律官。Lovell女士此前曾于2011年12月至2015年7月担任BCBSMA的高级副总裁and General Counsel。加入BCBSMA之前，Lovell从2007年3月到2011年12月担任Boston Medical Center行政and General Counsel高级副总裁。她此前也曾担任the Massachusetts Office of the Attorney的首席助理司法部长，以及the Massachusetts State Ethics Commission的执行董事。Lovell女士目前担任新英格兰法律基金会（New England Law Foundation）和合伙企业（Partnership，Inc.）的董事，并担任马萨诸塞州纳税人基金会（Massachusetts纳税人基金会）的受托人。她也是波士顿律师基金会（Boston Bar Foundation）的赠款委员会主席，也是Goodwill Industries of Massachusetts的投资委员会成员。Lovell在Hamilton College获得哲学学士学位，在Boston University School of Law获得法学博士学位。
- Stephanie Lovell will serve as a member of our board of directors upon completion of this separation. Ms. Lovell has served as the executive vice president, Medicare and chief legal officer for Blue Cross Blue Shield of Massachusetts, Inc., or BCBSMA, since July 2015. Ms. Lovell previously served as the senior vice president and general counsel of BCBSMA from December 2011 to July 2015. Prior to BCBSMA, Ms. Lovell was the senior vice president of administration and general counsel for Boston Medical Center from March 2007 to December 2011. She also previously served as the first assistant attorney general in the Massachusetts Office of the Attorney General and as the executive director for the Massachusetts State Ethics Commission. Ms. Lovell currently serves as a director of the New England Law Foundation and The Partnership, Inc., and as a trustee of the Massachusetts Taxpayers Foundation. She also chairs the grants committee of the Boston Bar Foundation and is a member of the investment committee of Goodwill Industries of Massachusetts.Ms. Lovell received a B.A. in philosophy from Hamilton College and a J.D. from Boston University School of Law.
- Waleed Hassanein
-
自1998年8月以来，我们的创始人Waleed Hassanein一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。创立TransMedics，Inc.之前。Hassanein博士在西罗克斯伯里VA Medical Center和哈佛医学院附属Brigham and Women&8217；s Hospital完成了为期三年的心脏外科研究奖学金。在他的研究金之前，Dr.Hassanein在Georgetown University Medical Center完成了两年的普通外科住院医师。Hassanein博士于1993年获得乔治敦大学（Georgetown University）的医学博士学位。在转到Georgetown University之前，Hassanein博士从1985年到1989年在Cairo University医学院就读，并持有the University of London普通教育证书。
Waleed Hassanein,, our founder, has served as our President and Chief Executive Officer and as a member of our board of directors since August 1998. Prior to founding TransMedics, Inc. Dr. Hassanein completed a three-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital, a Harvard Medical School affiliate. Prior to his research fellowship, Dr. Hassanein completed two years of general surgery residency at Georgetown University Medical Center. Dr. Hassanein earned his M.D. degree from Georgetown University in 1993. Prior to transferring to Georgetown University, Dr. Hassanein attended Cairo University School of Medicine from 1985 to 1989 and holds a General Certificate of Education from the University of London. - 自1998年8月以来，我们的创始人Waleed Hassanein一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。创立TransMedics，Inc.之前。Hassanein博士在西罗克斯伯里VA Medical Center和哈佛医学院附属Brigham and Women&8217；s Hospital完成了为期三年的心脏外科研究奖学金。在他的研究金之前，Dr.Hassanein在Georgetown University Medical Center完成了两年的普通外科住院医师。Hassanein博士于1993年获得乔治敦大学（Georgetown University）的医学博士学位。在转到Georgetown University之前，Hassanein博士从1985年到1989年在Cairo University医学院就读，并持有the University of London普通教育证书。
- Waleed Hassanein,, our founder, has served as our President and Chief Executive Officer and as a member of our board of directors since August 1998. Prior to founding TransMedics, Inc. Dr. Hassanein completed a three-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital, a Harvard Medical School affiliate. Prior to his research fellowship, Dr. Hassanein completed two years of general surgery residency at Georgetown University Medical Center. Dr. Hassanein earned his M.D. degree from Georgetown University in 1993. Prior to transferring to Georgetown University, Dr. Hassanein attended Cairo University School of Medicine from 1985 to 1989 and holds a General Certificate of Education from the University of London.
- Edward M. Basile
-
EdwardM.Basile，自2016年2月起担任我们的董事会成员。他目前已经退休。在King&Spalding律师事务所的25年任期内，Basile先生担任公司FDA和生命科学实践以及公司政策和薪酬委员会的主席。Basile先生的法律实践包括在美国食品和药物管理局（U.S.Food and Drug Administration）代表大型，中型和小型医疗器械，制药和生物技术公司。Basile先生还从1975年到1985年在FDA首席法律顾问办公室担任药物与生物制剂副首席法律顾问和执法副首席法律顾问。Basile先生在拉斐特学院（Lafayette College）获得工商管理硕士学位，在乔治华盛顿大学法学院（George Washington University Law School）获得法学博士学位。
Edward M. Basile, has served as a member of our board of directors since February 2016. He is currently retired. During his 25 year tenure with the law firm King & Spalding, Mr. Basile served as Chair of the firm’s FDA and Life Sciences Practice and on the firm’s Policy and Compensation Committees. Mr. Basile’s law practice included representing large, medium and small medical device, pharmaceutical, and biotechnology companies before the U.S. Food and Drug Administration. Mr. Basile also served in the Chief Counsel’s Office of FDA as Associate Chief Counsel for Drugs & Biologics and Associate Chief Counsel for Enforcement from 1975 to 1985. Mr. Basile received a BSME from Lafayette College and a JD from George Washington University Law School. - EdwardM.Basile，自2016年2月起担任我们的董事会成员。他目前已经退休。在King&Spalding律师事务所的25年任期内，Basile先生担任公司FDA和生命科学实践以及公司政策和薪酬委员会的主席。Basile先生的法律实践包括在美国食品和药物管理局（U.S.Food and Drug Administration）代表大型，中型和小型医疗器械，制药和生物技术公司。Basile先生还从1975年到1985年在FDA首席法律顾问办公室担任药物与生物制剂副首席法律顾问和执法副首席法律顾问。Basile先生在拉斐特学院（Lafayette College）获得工商管理硕士学位，在乔治华盛顿大学法学院（George Washington University Law School）获得法学博士学位。
- Edward M. Basile, has served as a member of our board of directors since February 2016. He is currently retired. During his 25 year tenure with the law firm King & Spalding, Mr. Basile served as Chair of the firm’s FDA and Life Sciences Practice and on the firm’s Policy and Compensation Committees. Mr. Basile’s law practice included representing large, medium and small medical device, pharmaceutical, and biotechnology companies before the U.S. Food and Drug Administration. Mr. Basile also served in the Chief Counsel’s Office of FDA as Associate Chief Counsel for Drugs & Biologics and Associate Chief Counsel for Enforcement from 1975 to 1985. Mr. Basile received a BSME from Lafayette College and a JD from George Washington University Law School.
- Thomas J. Gunderson
-
ThomasJ.Gunderson，自2016年8月起担任我们的董事会成员。Gunderson先生从2015年至今担任明尼阿波利斯心脏研究所基金会董事会主席，从2016年至今担任明尼苏达大学医疗行业领导研究所常驻执行官，作为2017年至今的Merit MedicalSystems，Inc.董事会成员，2015年至2017年担任美国心脏协会科学技术加速器委员会成员，1992年至2016年担任Piper Jaffray董事总经理兼高级研究分析师，专注于医疗技术公司。
Thomas J. Gunderson, has served as a member of our board of directors since August 2016. Mr. Gunderson has served as Chair of the Board of Directors at the Minneapolis Heart Institute Foundation from 2015 to present, as Executive in Residence at the University of Minnesota’s Medical Industry Leadership Institute from 2016 to present, as a member of the Board of Directors of Merit Medical Systems, Inc. from 2017 to present, as a member of American Heart Association Science and Technology Accelerator Committee from 2015 to 2017 and as managing director and senior research analyst at Piper Jaffray focus on medical technology companies from 1992 to 2016. - ThomasJ.Gunderson，自2016年8月起担任我们的董事会成员。Gunderson先生从2015年至今担任明尼阿波利斯心脏研究所基金会董事会主席，从2016年至今担任明尼苏达大学医疗行业领导研究所常驻执行官，作为2017年至今的Merit MedicalSystems，Inc.董事会成员，2015年至2017年担任美国心脏协会科学技术加速器委员会成员，1992年至2016年担任Piper Jaffray董事总经理兼高级研究分析师，专注于医疗技术公司。
- Thomas J. Gunderson, has served as a member of our board of directors since August 2016. Mr. Gunderson has served as Chair of the Board of Directors at the Minneapolis Heart Institute Foundation from 2015 to present, as Executive in Residence at the University of Minnesota’s Medical Industry Leadership Institute from 2016 to present, as a member of the Board of Directors of Merit Medical Systems, Inc. from 2017 to present, as a member of American Heart Association Science and Technology Accelerator Committee from 2015 to 2017 and as managing director and senior research analyst at Piper Jaffray focus on medical technology companies from 1992 to 2016.
- David Weill
-
David Weill自2016年以来一直担任威尔咨询集团（Weill Consulting Group）的负责人，该集团是一家专注于器官移植和肺部疾病的生物医学咨询集团。Weill博士参与移植和晚期肺部疾病领域超过20年，指导临床项目并为那些患有严重肺部疾病的患者提供护理。Weill博士于2005年至2016年担任斯坦福大学医学中心肺和心肺移植计划的主任，并且是斯坦福晚期肺部疾病中心的前任主任。Weill博士在杜兰大学（Tulane University）获得文学学士学位，并在杜兰大学医学院（Tulane University Medical School）获得医学博士学位。他在德州大学西南分校帕克兰医院（Parkland Hospital，University of Texas Southwestern）完成内科实习和住院医师资格，并在科罗拉多大学丹佛分校（University of Colorado at Denver）和健康科学中心（Health Sciences Center）完成肺与危重症医学和肺移植的研究金。
David Weill, has served since 2016 as Principal of the Weill Consulting Group, a biomedical consulting group focusing on organ transplantation and lung disease. Dr. Weill has been involved in the transplant and advanced lung disease fields for over 20 years, directing clinical programs and providing care to those afflicted with significant lung diseases. Dr. Weill served as Director of the Lung and Heart-Lung Transplant Program at Stanford University Medical Center from 2005 until 2016 and is the former Director of the Stanford Center for Advanced Lung Diseases. Dr. Weill received his Bachelor of Arts from Tulane University and his M.D. degree from Tulane University Medical School. He completed his Internship and Residency in Internal Medicine at Parkland Hospital, University of Texas Southwestern and his Fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation at the University of Colorado at Denver and Health Sciences Center. - David Weill自2016年以来一直担任威尔咨询集团（Weill Consulting Group）的负责人，该集团是一家专注于器官移植和肺部疾病的生物医学咨询集团。Weill博士参与移植和晚期肺部疾病领域超过20年，指导临床项目并为那些患有严重肺部疾病的患者提供护理。Weill博士于2005年至2016年担任斯坦福大学医学中心肺和心肺移植计划的主任，并且是斯坦福晚期肺部疾病中心的前任主任。Weill博士在杜兰大学（Tulane University）获得文学学士学位，并在杜兰大学医学院（Tulane University Medical School）获得医学博士学位。他在德州大学西南分校帕克兰医院（Parkland Hospital，University of Texas Southwestern）完成内科实习和住院医师资格，并在科罗拉多大学丹佛分校（University of Colorado at Denver）和健康科学中心（Health Sciences Center）完成肺与危重症医学和肺移植的研究金。
- David Weill, has served since 2016 as Principal of the Weill Consulting Group, a biomedical consulting group focusing on organ transplantation and lung disease. Dr. Weill has been involved in the transplant and advanced lung disease fields for over 20 years, directing clinical programs and providing care to those afflicted with significant lung diseases. Dr. Weill served as Director of the Lung and Heart-Lung Transplant Program at Stanford University Medical Center from 2005 until 2016 and is the former Director of the Stanford Center for Advanced Lung Diseases. Dr. Weill received his Bachelor of Arts from Tulane University and his M.D. degree from Tulane University Medical School. He completed his Internship and Residency in Internal Medicine at Parkland Hospital, University of Texas Southwestern and his Fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation at the University of Colorado at Denver and Health Sciences Center.
- James R. Tobin
-
James R. Tobin，自2011年起担任董事会主席。1999年至2009年，他担任医疗器械公司Boston Scientific Corporation的退休总裁兼首席执行官。在加入Boston Scientific之前，他曾担任Biogen Inc.的总裁兼首席执行官，从1994年到1997年担任其总裁兼首席运营官。在Biogen之前，他在百特国际公司（Baxter International Inc.）工作了22年，从财务分析师晋升为总裁兼首席运营官。他目前担任Corindus Vascular Robotics、Globus Medical Inc.、Oxford Immunotec, Inc.（上市公司）和Resolys Bio， Inc.（私人公司）的董事。他还曾在Curis， Inc.（1995年至2015年）、Medical Simulation Corp（2012年至2018年）、CardioDX, Inc（2014年至2017年）、Chiasma, Inc（2015年至2016年）和Aptus Endosystems， Inc（2011年至2015年）的董事会任职。他持有Harvard College的学士学位和Harvard Business School的工商管理硕士学位。他还曾在美国海军担任中尉。
James R. Tobin, has served as Chairman of board of directors since 2011. Mr. Tobin is the retired President and CEO of Boston Scientific Corporation, a medical device company, where he served from 1999 to 2009. Prior to Boston Scientific, Mr. Tobin was the President and CEO of Biogen Inc., and, from 1994 to 1997 its President and Chief Operating Officer. Before Biogen, Mr. Tobin spent 22 years with Baxter International Inc., rising from Financial Analyst to President and Chief Operating Officer. Mr. Tobin currently serves as a director of Corindus Vascular Robotics, Globus Medical Inc., Oxford Immunotec, Inc., each of which are public companies, and Resolys Bio, Inc., a private company. Mr. Tobin has also served on the boards of Curis, Inc., from 1995 to 2015 Medical Simulation Corp, from 2012 to 2018 CardioDX, Inc., from 2014 to 2017 Chiasma, Inc., from 2015 to 2016 and Aptus Endosystems, Inc. from 2011 to 2015. Mr. Tobin holds an AB from Harvard College and an MBA from Harvard Business School. Mr. Tobin also served to Lieutenant in the U.S. Navy. - James R. Tobin，自2011年起担任董事会主席。1999年至2009年，他担任医疗器械公司Boston Scientific Corporation的退休总裁兼首席执行官。在加入Boston Scientific之前，他曾担任Biogen Inc.的总裁兼首席执行官，从1994年到1997年担任其总裁兼首席运营官。在Biogen之前，他在百特国际公司（Baxter International Inc.）工作了22年，从财务分析师晋升为总裁兼首席运营官。他目前担任Corindus Vascular Robotics、Globus Medical Inc.、Oxford Immunotec, Inc.（上市公司）和Resolys Bio， Inc.（私人公司）的董事。他还曾在Curis， Inc.（1995年至2015年）、Medical Simulation Corp（2012年至2018年）、CardioDX, Inc（2014年至2017年）、Chiasma, Inc（2015年至2016年）和Aptus Endosystems， Inc（2011年至2015年）的董事会任职。他持有Harvard College的学士学位和Harvard Business School的工商管理硕士学位。他还曾在美国海军担任中尉。
- James R. Tobin, has served as Chairman of board of directors since 2011. Mr. Tobin is the retired President and CEO of Boston Scientific Corporation, a medical device company, where he served from 1999 to 2009. Prior to Boston Scientific, Mr. Tobin was the President and CEO of Biogen Inc., and, from 1994 to 1997 its President and Chief Operating Officer. Before Biogen, Mr. Tobin spent 22 years with Baxter International Inc., rising from Financial Analyst to President and Chief Operating Officer. Mr. Tobin currently serves as a director of Corindus Vascular Robotics, Globus Medical Inc., Oxford Immunotec, Inc., each of which are public companies, and Resolys Bio, Inc., a private company. Mr. Tobin has also served on the boards of Curis, Inc., from 1995 to 2015 Medical Simulation Corp, from 2012 to 2018 CardioDX, Inc., from 2014 to 2017 Chiasma, Inc., from 2015 to 2016 and Aptus Endosystems, Inc. from 2011 to 2015. Mr. Tobin holds an AB from Harvard College and an MBA from Harvard Business School. Mr. Tobin also served to Lieutenant in the U.S. Navy.
- Merilee Raines
-
Merilee Raines ，一直担任Watts Water Technologies, Inc.的董事会成员。Raines女士被任命为TransMedics Group公司的董事会成员，TransMedics Group公司是一家从事器官移植治疗的医疗技术公司，自2021年1月1日起生效。她还担任审计委员会成员，并将成为主席，自2021年6月1日起生效。Raines女士还曾在Aranta Therapeutics，Inc.的董事会任职，Aranta Therapeutics，Inc.是一家生物制药公司，专注于宠物伴侣市场的许可、开发和商业化产品。Raines女士目前是Excelitas Technologies Corporation的董事会成员，Excelitas Technologies Corporation是一家私营的全球工业技术公司，提供传感和检测解决方案，并担任其审计委员会主席。Raines女士是Dead River Company的董事会成员，Dead River Company是一家私营能源产品分销商，并在其财务和风险管理委员会任职。Raines女士此前曾是Affymetrix, Inc.的董事会成员，Affymetrix, Inc.是一家生命科学产品和分子诊断产品的上市供应商，在2015年1月至2016年4月期间，赛默飞世尔科学公司收购了Affymetrix。Raines女士此前还曾在PetVet Care Centers LLC的董事会任职。Raines女士于2003年10月至2013年5月退休期间，曾担任爱德士，Inc.的首席财务官，主要向伴侣动物健康市场提供诊断和IT产品及服务。Raines女士是注册会计师非活跃状态。1977年，她获得了鲍登学院的数学学士学位。1979年，她获得了芝加哥大学的硕士学位。
Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago. - Merilee Raines ，一直担任Watts Water Technologies, Inc.的董事会成员。Raines女士被任命为TransMedics Group公司的董事会成员，TransMedics Group公司是一家从事器官移植治疗的医疗技术公司，自2021年1月1日起生效。她还担任审计委员会成员，并将成为主席，自2021年6月1日起生效。Raines女士还曾在Aranta Therapeutics，Inc.的董事会任职，Aranta Therapeutics，Inc.是一家生物制药公司，专注于宠物伴侣市场的许可、开发和商业化产品。Raines女士目前是Excelitas Technologies Corporation的董事会成员，Excelitas Technologies Corporation是一家私营的全球工业技术公司，提供传感和检测解决方案，并担任其审计委员会主席。Raines女士是Dead River Company的董事会成员，Dead River Company是一家私营能源产品分销商，并在其财务和风险管理委员会任职。Raines女士此前曾是Affymetrix, Inc.的董事会成员，Affymetrix, Inc.是一家生命科学产品和分子诊断产品的上市供应商，在2015年1月至2016年4月期间，赛默飞世尔科学公司收购了Affymetrix。Raines女士此前还曾在PetVet Care Centers LLC的董事会任职。Raines女士于2003年10月至2013年5月退休期间，曾担任爱德士，Inc.的首席财务官，主要向伴侣动物健康市场提供诊断和IT产品及服务。Raines女士是注册会计师非活跃状态。1977年，她获得了鲍登学院的数学学士学位。1979年，她获得了芝加哥大学的硕士学位。
- Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago.
高管简历
中英对照 | 中文 | 英文- Waleed Hassanein
自1998年8月以来，我们的创始人Waleed Hassanein一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。创立TransMedics，Inc.之前。Hassanein博士在西罗克斯伯里VA Medical Center和哈佛医学院附属Brigham and Women&8217；s Hospital完成了为期三年的心脏外科研究奖学金。在他的研究金之前，Dr.Hassanein在Georgetown University Medical Center完成了两年的普通外科住院医师。Hassanein博士于1993年获得乔治敦大学（Georgetown University）的医学博士学位。在转到Georgetown University之前，Hassanein博士从1985年到1989年在Cairo University医学院就读，并持有the University of London普通教育证书。
Waleed Hassanein,, our founder, has served as our President and Chief Executive Officer and as a member of our board of directors since August 1998. Prior to founding TransMedics, Inc. Dr. Hassanein completed a three-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital, a Harvard Medical School affiliate. Prior to his research fellowship, Dr. Hassanein completed two years of general surgery residency at Georgetown University Medical Center. Dr. Hassanein earned his M.D. degree from Georgetown University in 1993. Prior to transferring to Georgetown University, Dr. Hassanein attended Cairo University School of Medicine from 1985 to 1989 and holds a General Certificate of Education from the University of London.- 自1998年8月以来，我们的创始人Waleed Hassanein一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。创立TransMedics，Inc.之前。Hassanein博士在西罗克斯伯里VA Medical Center和哈佛医学院附属Brigham and Women&8217；s Hospital完成了为期三年的心脏外科研究奖学金。在他的研究金之前，Dr.Hassanein在Georgetown University Medical Center完成了两年的普通外科住院医师。Hassanein博士于1993年获得乔治敦大学（Georgetown University）的医学博士学位。在转到Georgetown University之前，Hassanein博士从1985年到1989年在Cairo University医学院就读，并持有the University of London普通教育证书。
- Waleed Hassanein,, our founder, has served as our President and Chief Executive Officer and as a member of our board of directors since August 1998. Prior to founding TransMedics, Inc. Dr. Hassanein completed a three-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital, a Harvard Medical School affiliate. Prior to his research fellowship, Dr. Hassanein completed two years of general surgery residency at Georgetown University Medical Center. Dr. Hassanein earned his M.D. degree from Georgetown University in 1993. Prior to transferring to Georgetown University, Dr. Hassanein attended Cairo University School of Medicine from 1985 to 1989 and holds a General Certificate of Education from the University of London.
- Tamer Khayal
Tamer Khayal，自2018年1月起担任我们的首席商务官。他曾于2006年至2017年担任我们的首席医疗官兼临床开发Vice President，并于2001年至2006年担任我们的临床开发总监。加入TransMedics公司之前，他曾担任Zentiva Group公司（制药公司）的临床事务董事6年，在那里他曾领导公司的中东和非洲业务的临床研究、监管备案和临床销售培训。在他受雇于制药行业之前，Khayal博士是一名执业医师。Khayal博士在伦敦大学（University of London）获得普通教育证书，在开罗大学医学院（Cairo University School of Medicine）获得医学博士学位。
Tamer Khayal,has served as Chief Commercial Officer since January 2018. He served as Chief Medical Officer and Vice President of Clinical Development from 2006 to 2017 and as Director of Clinical Development from 2001 to 2006. Prior to joining TransMedics, Dr. Khayal served for six years as Director of Clinical Affairs for Zentiva Group, a.s., a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company's Middle East and Africa operations. Prior to his employment in the pharmaceutical industry, Dr. Khayal was a practicing physician. Dr. Khayal received a General Certificate of Education from the University of London and a M.D. degree from Cairo University School of Medicine.- Tamer Khayal，自2018年1月起担任我们的首席商务官。他曾于2006年至2017年担任我们的首席医疗官兼临床开发Vice President，并于2001年至2006年担任我们的临床开发总监。加入TransMedics公司之前，他曾担任Zentiva Group公司（制药公司）的临床事务董事6年，在那里他曾领导公司的中东和非洲业务的临床研究、监管备案和临床销售培训。在他受雇于制药行业之前，Khayal博士是一名执业医师。Khayal博士在伦敦大学（University of London）获得普通教育证书，在开罗大学医学院（Cairo University School of Medicine）获得医学博士学位。
- Tamer Khayal,has served as Chief Commercial Officer since January 2018. He served as Chief Medical Officer and Vice President of Clinical Development from 2006 to 2017 and as Director of Clinical Development from 2001 to 2006. Prior to joining TransMedics, Dr. Khayal served for six years as Director of Clinical Affairs for Zentiva Group, a.s., a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company's Middle East and Africa operations. Prior to his employment in the pharmaceutical industry, Dr. Khayal was a practicing physician. Dr. Khayal received a General Certificate of Education from the University of London and a M.D. degree from Cairo University School of Medicine.
- Gerardo Hernandez
Gerardo Hernandez，自2024年12月起担任TransMedics Group，Inc. 首席财务官兼财务主管。在加入TransMedics之前，Hernandez先生曾于2020年至2024年在阿尔尼拉姆制药担任财务副总裁、企业财务规划和分析主管，在那里他支持公司从一家美国临床阶段组织转变为一家全球性商业企业。他领导了该公司的全球绩效分析和财务规划流程。在加入Alnylam之前，Hernandez先生于2019年1月至2020年1月期间担任Takeda Pharmaceuticals Co Ltd的企业财务规划和分析整合主管。在此之前，他曾在Shire plc担任过多个职务，包括从2010年12月到2019年1月被武田收购之前的企业财务规划与分析主管。Hernandez先生于1994年9月至2010年6月期间在联合利华 PLC的财务机构任职。Hernandez先生在威斯康星大学拉克罗斯分校获得金融理学学士学位，并在巴西圣保罗的Funda o Getulio Vargas获得战略和经济学MBA学位。
Gerardo Hernandez,has served as TransMedics Group, Inc. Chief Financial Officer and Treasurer since December 2024. Prior to joining TransMedics, Mr. Hernandez served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals from 2020 to 2024 where he supported the company through its transformation from a U.S. clinical-stage organization to a global commercial enterprise. He led its global performance analysis and its financial planning processes. Before joining Alnylam, Mr. Hernandez served as Head of Corporate Financial Planning & Analysis Integration of Takeda Pharmaceuticals Co Ltd from January 2019 until January 2020. Prior to that, he held various roles at Shire plc, including Head of Corporate Financial Planning & Analysis from December 2010 until its acquisition by Takeda in January 2019. Mr. Hernandez held roles in the finance organization of Unilever plc from September 1994 until June 2010. Mr. Hernandez received a Bachelor of Science Degree in Finance from the University of Wisconsin, La Crosse and an MBA in Strategy and Economics from Fundao Getulio Vargas, Sao Paulo, Brazil.- Gerardo Hernandez，自2024年12月起担任TransMedics Group，Inc. 首席财务官兼财务主管。在加入TransMedics之前，Hernandez先生曾于2020年至2024年在阿尔尼拉姆制药担任财务副总裁、企业财务规划和分析主管，在那里他支持公司从一家美国临床阶段组织转变为一家全球性商业企业。他领导了该公司的全球绩效分析和财务规划流程。在加入Alnylam之前，Hernandez先生于2019年1月至2020年1月期间担任Takeda Pharmaceuticals Co Ltd的企业财务规划和分析整合主管。在此之前，他曾在Shire plc担任过多个职务，包括从2010年12月到2019年1月被武田收购之前的企业财务规划与分析主管。Hernandez先生于1994年9月至2010年6月期间在联合利华 PLC的财务机构任职。Hernandez先生在威斯康星大学拉克罗斯分校获得金融理学学士学位，并在巴西圣保罗的Funda o Getulio Vargas获得战略和经济学MBA学位。
- Gerardo Hernandez,has served as TransMedics Group, Inc. Chief Financial Officer and Treasurer since December 2024. Prior to joining TransMedics, Mr. Hernandez served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals from 2020 to 2024 where he supported the company through its transformation from a U.S. clinical-stage organization to a global commercial enterprise. He led its global performance analysis and its financial planning processes. Before joining Alnylam, Mr. Hernandez served as Head of Corporate Financial Planning & Analysis Integration of Takeda Pharmaceuticals Co Ltd from January 2019 until January 2020. Prior to that, he held various roles at Shire plc, including Head of Corporate Financial Planning & Analysis from December 2010 until its acquisition by Takeda in January 2019. Mr. Hernandez held roles in the finance organization of Unilever plc from September 1994 until June 2010. Mr. Hernandez received a Bachelor of Science Degree in Finance from the University of Wisconsin, La Crosse and an MBA in Strategy and Economics from Fundao Getulio Vargas, Sao Paulo, Brazil.
- Nicholas Corcoran
Nicholas Corcoran，自2023年1月起担任TransMedics Group，Inc.供应链和运营高级副总裁。在加入TransMedics之前，Corcoran先生自2022年4月起在史赛克公司担任部门运营（联合替代）副总裁，管理该部门的整个供应链，包括内部制造站点和外部供应合作伙伴，并于2020年至2022年担任部门和商业运营（Spine）副总裁，于2018年至2020年担任部门运营高级总监，此前担任全球采购总监。在加入史赛克之前，Corcoran先生还曾在沃特世公司和英特尔公司担任过各种供应链和运营职务。Corcoran先生在东南理工大学获得金融和经济学学士学位，在都柏林大学学院Smurfit商学院获得供应链管理商业硕士学位。
Nicholas Corcoran,has served as TransMedics Group, Inc. Senior Vice President of Supply Chain and Operations since January 2023. Prior to joining TransMedics, Mr. Corcoran served as Vice President of Division Operations (Joint Replacement) at Stryker Corporation since April 2022, managing the division's entire supply chain, including internal manufacturing sites and external supply partners, and as Vice President of Division and Commercial Operations (Spine) from 2020 until 2022, Senior Director of Division Operations from 2018 until 2020, and previously as Director of Global Sourcing. Prior to Stryker, Mr. Corcoran also held a variety of supply chain and operations roles at Waters Corporation and Intel Corporation. Mr. Corcoran received a Bachelor's Degree in Finance and Economics from South East Technological University and a Master's of Business in Supply Chain Management from The Smurfit School of Business, University College Dublin.- Nicholas Corcoran，自2023年1月起担任TransMedics Group，Inc.供应链和运营高级副总裁。在加入TransMedics之前，Corcoran先生自2022年4月起在史赛克公司担任部门运营（联合替代）副总裁，管理该部门的整个供应链，包括内部制造站点和外部供应合作伙伴，并于2020年至2022年担任部门和商业运营（Spine）副总裁，于2018年至2020年担任部门运营高级总监，此前担任全球采购总监。在加入史赛克之前，Corcoran先生还曾在沃特世公司和英特尔公司担任过各种供应链和运营职务。Corcoran先生在东南理工大学获得金融和经济学学士学位，在都柏林大学学院Smurfit商学院获得供应链管理商业硕士学位。
- Nicholas Corcoran,has served as TransMedics Group, Inc. Senior Vice President of Supply Chain and Operations since January 2023. Prior to joining TransMedics, Mr. Corcoran served as Vice President of Division Operations (Joint Replacement) at Stryker Corporation since April 2022, managing the division's entire supply chain, including internal manufacturing sites and external supply partners, and as Vice President of Division and Commercial Operations (Spine) from 2020 until 2022, Senior Director of Division Operations from 2018 until 2020, and previously as Director of Global Sourcing. Prior to Stryker, Mr. Corcoran also held a variety of supply chain and operations roles at Waters Corporation and Intel Corporation. Mr. Corcoran received a Bachelor's Degree in Finance and Economics from South East Technological University and a Master's of Business in Supply Chain Management from The Smurfit School of Business, University College Dublin.
- Matthew Forsyth
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Giovanni Cecere
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介